Skip to main content

Table 1 Clinicopathologic characteristics of patients

From: Effect of total number of harvested lymph nodes on survival outcomes after curative resection for gastric adenocarcinoma: findings from an eastern high-volume gastric cancer center

Clinicopathologic variable Mean (SD)/ Frequency (%) n = 4049
Age, in years
 Mean, SD 57.6 (11.9)
  < 65 years 2722 (67.2%)
  ≥ 65 years 1327 (32.8%)
Sex
 Male 2694 (66.5%)
 Female 1355 (33.5%)
BMI, in kg/m2 23.7 (3.1)
ASA
 I 1540 (38.0%)
 I 1991 (49.2%)
 III 187 (4.6%)
 Unknown 331 (8.2%)
pT size, in cm 4.6 (2.8)
pT category
 T1 2049 (50.6%)
 T2 595 (14.7%)
 T3 787 (19.4%)
 T4 618 (15.3%)
pN category
 N0 2465 (60.9%)
 N1 550 (13.6%)
 N2 440 (10.9%)
 N3 594 (14.7%)
Total number of pathologically positive lymph nodes 2.8 (6.3)
Total number of lymph nodes examined
 Mean, SD 42.9 (15.9)
 0–30 889 (22.0%)
 31–45 1597 (39.4%)
  > 45 1563 (38.6%)
pStage
 IA 1815 (44.8%)
 IB 501 (12.4%)
 IIA 423 (10.4%)
 IIB 330 (8.2%)
 IIIA 303 (7.5%)
 IIIB 341 (8.4%)
 IIIC 336 (8.3%)
Tumor location
 Proximal 683 (16.9%)
 Middle 1370 (33.8%)
 Distal 1916 (47.3%)
 Whole 80 (2.0%)
Histologic gradea
 Differentiated 1542 (38.1%)
 Undifferentiated 2456 (60.7%)
 Others 49 (1.2%)
 Unknown 2 (0.05%)
Borrmann type
 0 2214 (54.7%)
 I 51 (1.3%)
 II 374 (9.2%)
 III 1269 (31.3%)
 IV 121 (3.0%)
 V 19 (0.5%)
 Unknown 1 (0.02%)
Lauren type
 Intestinal 1899 (46.9%)
 Diffuse 1644 (40.6%)
 Mixed 359 (8.9%)
 Indeterminate/Unknown 147 (3.6%)
Lymphovascular invasion
 Present 1596 (39.4%)
 Absent 2340 (57.8%)
 Unknown 113 (2.8%)
Perineural invasion
 Present 948 (23.4%)
 Absent 2293 (56.6%)
 Unknown 808 (20.0%)
Resection type
 Subtotal 2892 (71.4%)
 Total 988 (24.4%)
 Extended 169 (4.2%)
Extent of lymph node dissection
 D1 126 (3.1%)
 D2 3867 (95.5%)
  > D2 46 (1.1%)
 Unknown 10 (0.2%)
Adjuvant chemotherapyb
 Yes 1002 (24.7%)
 No 3012 (74.4%)
 Unknown 35 (0.9%)
  1. Abbreviations: BMI body mass index, ASA American Society of Anesthesiology, pT pathologic tumor, pN pathologic nodal status
  2. aDifferentiated histology included papillary adenocarcinoma, well-differentiated tubular adenocarcinoma, and moderately differentiated adenocarcinoma. Undifferentiated histology included poorly differentiated adenocarcinoma, signet ring cell adenocarcinoma, and mucinous carcinoma. Others included adenosquamous, squamous, neuroendocrine, etc
  3. bAdjuvant chemotherapy was indicated in patients with Stage II disease and higher. Adjuvant chemotherapy after publication of S1 adjuvant therapy trial and initiation and subsequent publication of adjuvant capecitabine + oxaliplatin (XELOX) trial were either of the two. Prior to these trials, 5-fluorouracil-based chemotherapy was used